BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 14671631)

  • 21. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration.
    Deng M; Gui X; Kim J; Xie L; Chen W; Li Z; He L; Chen Y; Chen H; Luo W; Lu Z; Xie J; Churchill H; Xu Y; Zhou Z; Wu G; Yu C; John S; Hirayasu K; Nguyen N; Liu X; Huang F; Li L; Deng H; Tang H; Sadek AH; Zhang L; Huang T; Zou Y; Chen B; Zhu H; Arase H; Xia N; Jiang Y; Collins R; You MJ; Homsi J; Unni N; Lewis C; Chen GQ; Fu YX; Liao XC; An Z; Zheng J; Zhang N; Zhang CC
    Nature; 2018 Oct; 562(7728):605-609. PubMed ID: 30333625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel oncogenic role for urokinase receptor in leukemia cells: molecular sponge for oncosuppressor microRNAs.
    Li Santi A; Gorrasi A; Alfieri M; Montuori N; Ragno P
    Oncotarget; 2018 Jun; 9(45):27823-27834. PubMed ID: 29963240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma.
    Kouhpayeh S; Andalib A; Gharagozloo M; Sanei MH; Esmaeil N; Maracy MR
    Adv Biomed Res; 2017; 6():108. PubMed ID: 28904936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression.
    Ciavarella S; Laurenzana A; De Summa S; Pilato B; Chillà A; Lacalamita R; Minoia C; Margheri F; Iacobazzi A; Rana A; Merchionne F; Fibbi G; Del Rosso M; Guarini A; Tommasi S; Serratì S
    BMC Cancer; 2017 Mar; 17(1):215. PubMed ID: 28340565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment.
    Selleri C; Montuori N; Salvati A; Serio B; Pesapane A; Ricci P; Gorrasi A; Li Santi A; Hoyer-Hansen G; Ragno P
    Oncotarget; 2016 Sep; 7(37):60206-60217. PubMed ID: 27517491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease detection using flow cytometry: Applications in acute leukemia.
    Chatterjee T; Mallhi RS; Venkatesan S
    Med J Armed Forces India; 2016 Apr; 72(2):152-6. PubMed ID: 27257325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.
    Shen J; Wang Q; Wang J; Su GH; Wang J; Guo SH; Liu YA; Wu Z; Liu RF; Li X; Guo XJ; Cao J; Zhang YH; Wang ZY
    Oncol Lett; 2015 Oct; 10(4):2403-2409. PubMed ID: 26622860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).
    Bekdash A; Darwish M; Timsah Z; Kassab E; Ghanem H; Najjar V; Ghosn M; Nasser S; El-Hajj H; Bazerbachi A; Liu S; Leppla SH; Frankel AE; Abi-Habib RJ
    Transl Oncol; 2015 Oct; 8(5):347-357. PubMed ID: 26500025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells.
    Alfano D; Gorrasi A; Li Santi A; Ricci P; Montuori N; Selleri C; Ragno P
    J Cell Mol Med; 2015 Sep; 19(9):2262-72. PubMed ID: 26082201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer associated fibroblasts in hematological malignancies.
    Raffaghello L; Vacca A; Pistoia V; Ribatti D
    Oncotarget; 2015 Feb; 6(5):2589-603. PubMed ID: 25474039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of molecular modeling to urokinase inhibitors development.
    Sulimov VB; Katkova EV; Oferkin IV; Sulimov AV; Romanov AN; Roschin AI; Beloglazova IB; Plekhanova OS; Tkachuk VA; Sadovnichiy VA
    Biomed Res Int; 2014; 2014():625176. PubMed ID: 24967388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).
    Xu X; Cai Y; Wei Y; Donate F; Juarez J; Parry G; Chen L; Meehan EJ; Ahn RW; Ugolkov A; Dubrovskyi O; O'Halloran TV; Huang M; Mazar AP
    PLoS One; 2014; 9(1):e85349. PubMed ID: 24465541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.
    O'Halloran TV; Ahn R; Hankins P; Swindell E; Mazar AP
    Theranostics; 2013; 3(7):496-506. PubMed ID: 23843897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The soluble form of LR11 protein is a regulator of hypoxia-induced, urokinase-type plasminogen activator receptor (uPAR)-mediated adhesion of immature hematological cells.
    Nishii K; Nakaseko C; Jiang M; Shimizu N; Takeuchi M; Schneider WJ; Bujo H
    J Biol Chem; 2013 Apr; 288(17):11877-86. PubMed ID: 23486467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.
    Raghu H; Nalla AK; Gondi CS; Gujrati M; Dinh DH; Rao JS
    Mol Oncol; 2012 Feb; 6(1):33-47. PubMed ID: 22177802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.
    Mazar AP; Ahn RW; O'Halloran TV
    Curr Pharm Des; 2011; 17(19):1970-8. PubMed ID: 21711234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.
    Atfy M; Eissa M; Salah HE; El Shabrawy DA
    Med Oncol; 2012 Sep; 29(3):2063-9. PubMed ID: 21638078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects.
    Cancello R; Rouault C; Guilhem G; Bedel JF; Poitou C; Di Blasio AM; Basdevant A; Tordjman J; Clément K
    Obes Facts; 2011; 4(1):17-25. PubMed ID: 21372607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.
    Devy J; Ouchani F; Oudot C; Helesbeux JJ; Vanquelef E; Salesse S; Rabenoelina F; Al-Khara S; Letinois I; Duval O; Martiny L; Charpentier E
    Invest New Drugs; 2011 Oct; 29(5):730-41. PubMed ID: 20349265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of cell signalling by uPAR.
    Smith HW; Marshall CJ
    Nat Rev Mol Cell Biol; 2010 Jan; 11(1):23-36. PubMed ID: 20027185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.